Elizabeth A. Barrett - 03 Jan 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Executive Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 03 Jan 2022
Net transactions value: -$429,757
Form type: 4
Filing time: 07 Jan 2022, 07:38:53 UTC
Previous filing: 03 Aug 2021
Next filing: 02 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+105,689	+44%		345,188	03 Jan 2022	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$429,757	-46,968	-14%	$9.15	298,220	04 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-105,689	-100%	$0.000000^*	0	03 Jan 2022	Ordinary Shares	105,689		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3	The reporting person was granted RSUs on January 3, 2019 representing 317,065 ordinary shares. 33.33% of the RSUs vested on January 3, 2020. 33.33% of the RSUs vested in equal monthly installments through January 3, 2021. The remaining 33.33% of the RSUs vested on January 3, 2022.